New therapies for type 2 diabetes based on glucagon-like peptide 1

Marzieh Salehi, David A. D'Alessio

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.

Original languageEnglish (US)
Pages (from-to)382-389
Number of pages8
JournalCleveland Clinic journal of medicine
Volume73
Issue number4
DOIs
StatePublished - Apr 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'New therapies for type 2 diabetes based on glucagon-like peptide 1'. Together they form a unique fingerprint.

Cite this